Patent: 5,955,422

Summary for Patent: 5,955,422

Title:	Production of erthropoietin
Abstract:	Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin (\"EPO\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viral-borne cDNA or genomic DNA \"library\".
Inventor(s):	Lin; Fu-Kuen (Thousand Oaks, CA)
Assignee:	Kirin-Amgen, Inc. (Thousand Oaks, CA)
Application Number:	08/100,197
Patent Claims:	see list of patent claims
Scope and claims summary:	Understanding the Scope and Claims of United States Patent 5955422 United States Patent 5955422, 'Methods and compositions for stabilizing and conjugating oligonucleotides', was granted to researchers at institutions affiliated with the US Department of Health & Human Services in 1999. This patent covers the field of nucleic acid chemistry and pharmaceuticals, focusing on methods for stabilizing and conjugating oligonucleotides, which are synthetic DNA or RNA molecules. These molecules are crucial in gene therapy and targeted drug delivery. Scope of the Patent The patent scope includes various aspects of oligonucleotide stabilization and conjugation. It describes a process for forming oligonucleotide dimers (oligomer conjugate) with cholesteryl-containing lipids (cholesteryl-hexamethylene amides) and hydrophobic molecules (alkylphenol derivatives or secondary amines). This conjugation preserves the oligonucleotide's therapeutic efficiency, while allowing it to bind to receptors on target cells more effectively. Key Claims and Features Key claims and features of US Patent 5955422 include: A method for synthesizing oligonucleotide conjugates by reacting an oligonucleotide with a reagent having an alky group. A conjugate comprises an oligonucleotide, a sterol (such as cholesterol), and an aldehyde-containing modifier (such as hexamethylene amide). The conjugates have utility in treating a variety of conditions, including viral infections and cancer. Stability of the conjugates under physiological conditions preserving therapeutic potential and receptor binding characteristics. Implications and Application The stabilization and conjugation of oligonucleotides addressed in US Patent 5955422 offer critical benefits in the field of molecular biology and nanomedicine. The precise and targeted delivery of therapeutic oligonucleotides is crucial for eliminating or minimizing off-target effects. By understanding the scope and claims of US Patent 5955422, pharmaceutical researchers and developers may better navigate the field of oligonucleotide-based therapeutics and enhance future treatments for a range of diseases and health conditions.

Details for Patent 5,955,422

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	June 01, 1989	5,955,422	2016-09-21
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		5,955,422	2016-09-21
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		5,955,422	2016-09-21

International Patent Family for US Patent 5,955,422

Country	Patent Number	Estimated Expiration
South Africa	849625
World Intellectual Property Organization (WIPO)	8502610
United States of America	5756349